Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis
المؤلفون المشاركون
Paciaroni, Maurizio
Wong, Ka Sing
Ince, Birsen
Hu, Bo
Jeng, Jiann-Shing
Kutluk, Kursad
Lou, Min
Parfenov, Vladimir
Zamani, Babak
Paek, Dara
Min Han, Jung
del Aguila, Michael
Girotra, Shalini
Liu, Liping
المصدر
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-12، 12ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-12-01
دولة النشر
مصر
عدد الصفحات
12
التخصصات الرئيسية
الملخص EN
Aim.
Though combination of clopidogrel added to aspirin has been compared to aspirin alone in patients with stroke or transient ischemic attack, limited data exists on the relative efficacy and safety between clopidogrel and aspirin monotherapy in patients with a recent ischemic stroke.
We aimed to compare clopidogrel versus aspirin monotherapy in this population.
Methods.
PubMed, Embase, and CENTRAL databases were searched from inception to May 2018 to identify clinical trials and observational studies comparing clopidogrel versus aspirin for secondary prevention in patients with recent ischemic stroke within 12 months.
Pooled effect estimates were calculated using a random effects model and were reported as risk ratios with 95% confidence intervals.
Results.
Five studies meeting eligibility criteria were included in the analysis.
A total of 29,357 adult patients who had recent ischemic stroke received either clopidogrel ( n = 14 , 293 ) or aspirin ( n = 15 , 064 ) for secondary prevention.
Pairwise meta-analysis showed a statistically significant risk reduction in the occurrence of major adverse cardiovascular and cerebrovascular events (risk ratio 0.72 [95% CI, 0.53–0.97]), any ischemic or hemorrhagic stroke (0.76 [0.58, 0.99), and recurrent ischemic stroke (0.72 [0.55, 0.94]) in patients who received clopidogrel versus aspirin.
The risk of bleeding was also lower for clopidogrel versus aspirin (0.57 [0.45, 0.74]).
There was no difference in the rate of all-cause mortality between the two groups.
Conclusions.
The analysis showed lower risks of major adverse cardiovascular or cerebrovascular events, recurrent stroke, and bleeding events for clopidogrel monotherapy compared to aspirin.
These findings support clinical benefit for single antiplatelet therapy with clopidogrel over aspirin for secondary prevention in patients with recent ischemic stroke.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Paciaroni, Maurizio& Ince, Birsen& Hu, Bo& Jeng, Jiann-Shing& Kutluk, Kursad& Liu, Liping…[et al.]. 2019. Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis. Cardiovascular Therapeutics،Vol. 2019, no. 2019, pp.1-12.
https://search.emarefa.net/detail/BIM-1129152
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Paciaroni, Maurizio…[et al.]. Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis. Cardiovascular Therapeutics No. 2019 (2019), pp.1-12.
https://search.emarefa.net/detail/BIM-1129152
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Paciaroni, Maurizio& Ince, Birsen& Hu, Bo& Jeng, Jiann-Shing& Kutluk, Kursad& Liu, Liping…[et al.]. Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis. Cardiovascular Therapeutics. 2019. Vol. 2019, no. 2019, pp.1-12.
https://search.emarefa.net/detail/BIM-1129152
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1129152
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر